Saturday 17 October 2026 Export SANA’s income statement to Excel — free account

Sana Biotechnology, Inc.

In the quarter to June 2026, EPS grew 43.6% and free cash flow fell 5.46%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

2.27 0.21 −8.47%

Follow SANA

Alert me

Market cap: $740.9M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 36.83%

Capital & Financial Ratios $m

Market Cap 740.92

Revenue —

Net Income (211.82)

Free Cash Flow (133.99)

Net Debt (164.68)

Current Ratio 1.38

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 4.34

Past 5Y EPS Growth —

This Y EPS Growth 28.65%

Next Y EPS Growth 13.71%

Next Y revenue growth —

Next 5Y EPS Growth 14.37%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 66.36%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	209	156	143	165
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	214	161	149	171

	2023	2024	2025	Q'26
Payables	4	5	2	1
ST’ Debt	—	—	—	—
Other	—	—	40	91
	64	45	79	124

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(31.44%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(37)	(33)	—	—	—
’25	(49)	(33)	(29)	(33)	(144)
’24	(66)	(59)	(52)	(47)	(223)
’23	(79)	(59)	(64)	(52)	(254)
’22	(78)	(71)	(65)	(76)	(290)
’21	(50)	(41)	(50)	(110)	(251)
’20	(30)	(33)	(38)	(38)	(138)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(37)	(34)	—	—	—
’25	(49)	(33)	(29)	(33)	(143)
’24	(81)	(72)	(56)	(48)	(257)
’23	(81)	(60)	(66)	(66)	(274)
’22	(85)	(76)	(69)	(81)	(311)
’21	(56)	(51)	(59)	(115)	(281)
’20	(35)	(36)	(44)	(47)	(162)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.17)	(0.22)	—	—	—
’25	(0.21)	(0.39)	(0.16)	(0.21)	(0.96)
’24	(0.49)	(0.21)	(0.25)	(0.21)	(1.16)
’23	(0.43)	(0.59)	0.00	(0.45)	(1.46)
’22	(0.17)	(0.39)	(0.45)	(0.42)	(1.43)
’21	(1.52)	0.09	(0.46)	(0.60)	(2.14)
’20	(3.04)	(7.18)	(3.76)	(7.40)	(21.92)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	14.90	3.15	2.75	1.52	1.26	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	44.60	16.04	8.01	12.00	7.30
People
People	Employees	—	—	—	—	265	383	421	328	194	142
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	—	—	(13)	(138)	(285)	(356)	(269)	(283)	(267)	(244)
	EBT margin, %	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	(13)	(131)	(285)	(356)	(269)	(283)	(267)	(244)
	Depreciation	—	—	0	2	6	11	16	18	16	13
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	(0.07)	(26.67)	(21.92)	(2.14)	(1.43)	(1.46)	(1.16)	(0.96)
	Cash flow	—	—	(0.07)	(17.44)	(10.60)	(1.51)	(1.54)	(1.30)	(0.97)	(0.57)
	Capex	—	—	0.00	(5.33)	(1.83)	(0.18)	(0.11)	(0.10)	(0.14)	0.00
	Free cash flow	—	—	(0.07)	(22.77)	(12.44)	(1.69)	(1.65)	(1.41)	(1.11)	(0.57)
	Book value	—	—	0.18	(29.07)	(32.36)	4.38	2.65	1.48	1.08	0.64
	Shares, m	—	—	187	5	13	166	188	195	231	253
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	(13)	(86)	(138)	(251)	(290)	(254)	(223)	(144)
	Capex	—	—	0	(26)	(24)	(30)	(21)	(20)	(33)	0
	Free cash flow	—	—	(13)	(112)	(162)	(281)	(311)	(274)	(257)	(143)
Balance, $m
Balance, $m	Working capital	—	—	31	125	353	459	333	149	115	70
	Total debt	—	—	—	48	72	111	108	—	—	—
	Net debt	—	—	(31)	(139)	(378)	(551)	(430)	(209)	(156)	(143)
	Shareholders’ equity	—	—	33	(143)	(421)	729	499	288	251	161
Returns, %
Returns, %	ROA	—	—	(77.92)	(58.23)	(49.81)	(38.28)	(27.61)	(40.81)	(50.03)	(53.20)
	ROIC	—	—	0.00	0.00	0.00	(125.67)	(245.99)	(233.45)	(180.99)	(854.59)
	ROE	—	—	16.98	168.16	101.22	(231.64)	(43.90)	(72.00)	(99.17)	(118.70)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DNA Ginkgo Bioworks Holdings, Inc.	$791.9M	— (loss-making)	— (loss-making)	−48.49% (below 0%: shrinking)	n/m	−16.38% (below 0%: shrinking)	91.47%	(290.47%)	Compare
GERN Geron Corporation	$790.2M	— (loss-making)	— (loss-making)	+17.22% (above 0%: growing)	n/m	+41.82% (above 0%: growing)	83.92%	(21.74%)	Compare
SANA Sana Biotechnology, Inc.	$740.9M	— (loss-making)	—	—	n/m	−5.46% (below 0%: shrinking)	0.00%	0.00%
IVA Inventiva S.A. Sponsored ADR	$740.0M	— (loss-making)	— (loss-making)	−10.77% (below 0%: shrinking)	n/m	−20,989.22% (below 0%: shrinking)	0.00%	0.00%	Compare
LXRX Lexicon Pharmaceuticals, Inc.	$734.2M	— (loss-making)	— (loss-making)	−97.60% (below 0%: shrinking)	n/m	−154.09% (below 0%: shrinking)	94.36%	(3,835.26%)	Compare
IMMX Immix Biopharma, Inc.	$719.6M	— (loss-making)	—	—	n/m	−116.22% (below 0%: shrinking)	—	0.00%	Compare
ACHV Achieve Life Sciences, Inc.	$717.2M	— (loss-making)	—	+54.44% (above 0%: growing)	n/m	−19.01% (below 0%: shrinking)	0.00%	0.00%	Compare
FDMT 4D Molecular Therapeutics, Inc.	$711.0M	— (loss-making)	— (loss-making)	+25,106.67% (above 0%: growing)	n/m	−61.28% (below 0%: shrinking)	100.00%	(2,037.16%)	Compare
ANL Adlai Nortye Ltd. Sponsored ADR	$710.1M	—	—	—	—	+46.03% (above 0%: growing)	—	—	Compare
Median of peers	$726.9M	—	—	+3.22%	—	−40.14%	87.69%	(21.74%)

All 614 Biotechnology stocks →

Sana Biotechnology, Inc. (SANA) key facts

Sana Biotechnology, Inc. (SANA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SANA traded at $2.27, a market capitalization of $740.9 million.
Return on equity was −118.7% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.